GlobeNewsWire
02 Sept 2026, 21:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
RASONQUE demonstrated a 42% objective response rate and 89% disease control rate in a Phase 1/2 trial for patients with RAS mutant non-small cell lung cancer (NSCLC) other than RAS G12C. — Strong clinical efficacy in a large unmet need area (non-G12C RAS mutations) significantly increases the probability of success for the ongoing Phase 3 trial.
+0.70Revolution Medicines is conducting a global, randomized Phase 3 trial (RASolve 301) evaluating RASONQUE against docetaxel in previously treated RAS mutant NSCLC. — The progression to a pivotal Phase 3 trial represents a major step toward commercial expansion into the lung cancer market.
+0.50RASONQUE has already received FDA approval for the treatment of metastatic pancreatic adenocarcinoma. — Existing FDA approval for another indication validates the drug's safety and regulatory viability, reducing the overall risk profile for the company.
+0.40Continue reading
6 related stories
Search tags
The Phase 1/2 trial reported a manageable safety profile with Grade 3 treatment-related adverse events in 25% of patients and no Grade 4 or 5 events within the 160 mg to 220 mg dose range. — Low toxicity and a lack of severe adverse events support the likelihood of a favorable benefit-risk assessment by regulators.
+0.30Which stocks this story touches
Positive clinical data published in NEJM and recent FDA approval for RASONQUE provide strong validation for the company's oncology pipeline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
4h ago
